Citius Pharmaceuticals Inc.

1.19+0.1400+13.33%Vol 1.91M1Y Perf -42.93%
Aug 11th, 2022 16:00 DELAYED
BID1.18 ASK1.19
Open1.09 Previous Close1.05
Pre-Market- After-Market1.18
 - -  -0.01 -0.84%
Target Price
6.67 
Analyst Rating
Strong Buy 1.00
Potential %
460.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
23.65 
Earnings Rating
Strong Buy
Market Cap173.89M 
Earnings Date
11th Aug 2022
Alpha-0.01 Standard Deviation0.29
Beta1.56 

Today's Price Range

1.041.20

52W Range

0.83062.35

5 Year PE Ratio Range

-1.90-2.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
19.00%
1 Month
31.94%
3 Months
32.58%
6 Months
-21.19%
1 Year
-42.93%
3 Years
8.18%
5 Years
-59.11%
10 Years
-

TickerPriceChg.Chg.%
CTXR1.190.140013.33
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.08-0.0537.50
Q01 2022-0.06-0.060.00
Q04 2021-0.03-0.030.00
Q03 2021-0.05-0.050.00
Q02 2021-0.08-0.0450.00
Q01 2021--0.15-
Q03 2019-0.06-0.20-233.33
Q02 2019-0.20-0.200.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0544.44Positive
9/2022 QR-0.0544.44Positive
9/2022 FY-0.2212.00Positive
9/2023 FY0.19-32.14Negative
Next Report Date-
Estimated EPS Next Report-0.05
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.91M
Shares Outstanding146.13K
Shares Float133.82M
Trades Count4.29K
Dollar Volume2.20M
Avg. Volume873.92K
Avg. Weekly Volume847.48K
Avg. Monthly Volume621.01K
Avg. Quarterly Volume1.15M

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 1.19 per share at the end of the most recent trading day (a 13.33% change compared to the prior day closing price) with a volume of 1.91M shares and market capitalization of 173.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.

The one-year performance of Citius Pharmaceuticals Inc. stock is -42.93%, while year-to-date (YTD) performance is -22.73%. CTXR stock has a five-year performance of -59.11%. Its 52-week range is between 0.8306 and 2.35, which gives CTXR stock a 52-week price range ratio of 23.65%

Citius Pharmaceuticals Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.77%, a ROC of -23.91% and a ROE of -24.62%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6.67, which is +460.50% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Citius Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.06, ATR14 : 0.08, CCI20 : 179.45, Chaikin Money Flow : 0.09, MACD : 0.02, Money Flow Index : 73.78, ROC : 16.94, RSI : 73.98, STOCH (14,3) : 79.16, STOCH RSI : 0.43, UO : 60.11, Williams %R : -20.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

CEO: Myron Z. Holubiak

Telephone: +1 908 967-6677

Address: 11 Commerce Drive, Cranford 07016, NJ, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

65%35%

TipRanks News for CTXR

Thu, 26 May 2022 18:05 GMT Citius Pharmaceuticals (CTXR) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

Sat, 12 Feb 2022 12:37 GMT Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR) and Cybin (CYBN)

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 09:11 GMT Citius Pharmaceuticals (CTXR) Receives a Buy from Dawson James

- TipRanks. All rights reserved.

News

Stocktwits